{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:48:01Z","timestamp":1785206881328,"version":"3.55.0"},"reference-count":39,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Lynch syndrome (LS) is the most common inherited colorectal and endometrial cancer syndrome, caused by germline mutations in DNA mismatch repair (MMR) genes. It is also characterized by an increased risk of other tumors with lower prevalence, such as adrenal cortical carcinoma (ACC), an endocrine tumor with an incidence of &amp;lt;2 cases\/million individuals\/year. Most ACC developed during childhood are associated with hereditary syndromes. In adults, this association is not as well established as in children. Previous studies showed a 3.2% prevalence of LS among patients with ACC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Acquisition<\/jats:title>\n                  <jats:p>The objective of this study is to determine the prevalence of ACC in a Spanish LS cohort and their molecular and histological characteristics. This retrospective study includes 634 patients from 220 LS families registered between 1999 and 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Synthesis<\/jats:title>\n                  <jats:p>During the follow-up period, 3 patients were diagnosed with ACC (0.47%); all were carriers of a MSH2 germline mutation. The 3 ACC patients presented loss of expression of MSH2 and MSH6 proteins. One tumor analysis showed loss of heterozygosity of the MSH2 wildtype allele. Our findings support previous data that considered ACC as a LS spectrum tumor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>MMR protein immunohistochemistry screening could be an efficient strategy to detect LS in patients with ACC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa833","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T16:36:09Z","timestamp":1605285369000},"page":"318-325","source":"Crossref","is-referenced-by-count":36,"title":["Characteristics of Adrenocortical Carcinoma Associated With Lynch Syndrome"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-9170","authenticated-orcid":false,"given":"Marta","family":"Dom\u00e8nech","sequence":"first","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Medical Oncology Department, Catalan Institute of Oncology, ICO-Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Grau","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ares","family":"Solanes","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain"},{"name":"Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"del Valle","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrato","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pineda","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Due\u00f1as","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Pujol","sequence":"additional","affiliation":[{"name":"Pathology Department, Moises Broggi Hospital, Sant Joan Desp\u00ed, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxi","family":"L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Capell\u00e0","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-3512","authenticated-orcid":false,"given":"Joan","family":"Brunet","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Navarro","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Institut d\u2019Investigaci\u00f3 Biom\u00e9dica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"issue":"6","key":"2021122205334815100_CIT0001","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Clinical review: adrenocortical carcinoma: clinical update","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122205334815100_CIT0002","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg."},{"issue":"1","key":"2021122205334815100_CIT0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12672-015-0244-z","article-title":"5th International ACC Symposium: hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th International ACC Symposium session: not just for kids!","volume":"7","author":"Else","year":"2016","journal-title":"Horm Cancer."},{"issue":"3","key":"2021122205334815100_CIT0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MPH.0000000000000281","article-title":"Simultaneous adrenocortical carcinoma and neuroblastoma in an infant with a novel germline p53 mutation","volume":"37","author":"Courtney","year":"2015","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"2021122205334815100_CIT0005","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205334815100_CIT0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122205334815100_CIT0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-11-0679","article-title":"Adrenal involvement in MEN1. analysis of 715 cases from the groupe d\u2019etude des tumeurs endocrines database","volume":"166","author":"Gatta-Cherifi","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122205334815100_CIT0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10689-010-9416-8","article-title":"Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome","volume":"10","author":"Medina-Arana","year":"2011","journal-title":"Fam Cancer."},{"issue":"24","key":"2021122205334815100_CIT0009","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021122205334815100_CIT0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1210\/js.2019-00050","article-title":"Adrenal cortical carcinoma associated with lynch syndrome: a case report and review of literature","volume":"3","author":"Kaur","year":"2019","journal-title":"J Endocr Soc."},{"issue":"6","key":"2021122205334815100_CIT0011","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1210\/jc.2016-1460","article-title":"Familial adrenocortical carcinoma in association with lynch syndrome","volume":"101","author":"Challis","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"7-8 Pt 2","key":"2021122205334815100_CIT0012","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.lpm.2018.07.004","article-title":"Adrenocortical carcinoma (ACC): when and why should we consider germline testing?","volume":"47","author":"Petr","year":"2018","journal-title":"Presse Med."},{"issue":"12","key":"2021122205334815100_CIT0013","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/hupa.2000.20409","article-title":"Adrenocortical adenocarcinoma in an MSH2 carrier: coincidence or causal relation?","volume":"31","author":"Berends","year":"2000","journal-title":"Hum Pathol."},{"issue":"3","key":"2021122205334815100_CIT0014","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10689-017-0042-6","article-title":"Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome","volume":"17","author":"Wright","year":"2018","journal-title":"Fam Cancer."},{"issue":"8","key":"2021122205334815100_CIT0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/modpathol.3800150","article-title":"Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome","volume":"17","author":"Broaddus","year":"2004","journal-title":"Mod Pathol."},{"issue":"8","key":"2021122205334815100_CIT0016","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ajg.2014.186","article-title":"Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer","volume":"109","author":"Giardiello","year":"2014","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2021122205334815100_CIT0017","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1001\/jamaoncol.2017.0619","article-title":"Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies","volume":"3","author":"Ryan","year":"2017","journal-title":"JAMA Oncol."},{"issue":"9","key":"2021122205334815100_CIT0018","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2016-311403","article-title":"Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut."},{"issue":"15","key":"2021122205334815100_CIT0019","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2012.13088","article-title":"Identification of Lynch syndrome among patients with colorectal cancer","volume":"308","author":"Moreira","year":"2012","journal-title":"JAMA."},{"issue":"11","key":"2021122205334815100_CIT0020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer","volume":"38","author":"Mills","year":"2014","journal-title":"Am J Surg Pathol."},{"issue":"35","key":"2021122205334815100_CIT0021","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","article-title":"Feasibility of screening for Lynch syndrome among patients with colorectal cancer","volume":"26","author":"Hampel","year":"2008","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021122205334815100_CIT0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021122205334815100_CIT0023","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.humpath.2011.12.012","article-title":"Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature","volume":"43","author":"Karamurzin","year":"2012","journal-title":"Hum Pathol."},{"issue":"12","key":"2021122205334815100_CIT0024","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamadermatol.2014.1217","article-title":"Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm","volume":"150","author":"Everett","year":"2014","journal-title":"JAMA Dermatol."},{"issue":"11","key":"2021122205334815100_CIT0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","article-title":"Universal lynch syndrome screening should be performed in all upper tract urothelial carcinomas","volume":"42","author":"Ju","year":"2018","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"2021122205334815100_CIT0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ng.2854","article-title":"Application of a 5-tiered scheme for standardized classification of 2360 unique mismatch repair gene variants in the InSiGHT locus-specific database","volume":"46","author":"Thompson","year":"2014","journal-title":"Nat Genet."},{"issue":"3","key":"2021122205334815100_CIT0027","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut."},{"issue":"10","key":"2021122205334815100_CIT0028","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdz233","article-title":"Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Stjepanovic","year":"2019","journal-title":"Ann. Oncol"},{"issue":"29","key":"2021122205334815100_CIT0029","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-associated Lynch syndrome","volume":"36","author":"Broeke","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122205334815100_CIT0030","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet. Med"},{"issue":"10","key":"2021122205334815100_CIT0031","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41436-019-0489-y","article-title":"The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome","volume":"21","author":"Crosbie","year":"2019","journal-title":"Genet Med."},{"issue":"95","key":"2021122205334815100_CIT0032","first-page":"126","article-title":"Cancer registration: principles and methods. Statistical methods for registries","author":"Boyle","year":"1991","journal-title":"IARC Sci Publ"},{"key":"2021122205334815100_CIT0033","year":"2019"},{"issue":"3","key":"2021122205334815100_CIT0034","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1055-9965.EPI-16-0693","article-title":"Prevalence and penetrance of major genes and polygenes for colorectal cancer","volume":"26","author":"Win","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"6","key":"2021122205334815100_CIT0035","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gutjnl-2012-304356","article-title":"Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts","volume":"62","author":"Vasen","year":"2013","journal-title":"Gut."},{"issue":"June","key":"2021122205334815100_CIT0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"6733","author":"Le","year":"2017","journal-title":"Science"},{"issue":"13","key":"2021122205334815100_CIT0037","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2021122205334815100_CIT0038","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"key":"2021122205334815100_CIT0039","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.2147\/OTT.S167645","article-title":"Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer","volume":"11","author":"Salman","year":"2018","journal-title":"Onco Targets Ther."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa833\/34862211\/dgaa833.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/2\/318\/41849325\/dgaa833.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/2\/318\/41849325\/dgaa833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:39:27Z","timestamp":1640151567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/2\/318\/5981336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,13]]},"published-print":{"date-parts":[[2021,1,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa833","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,11,13]]}}}